The global erythromelalgia treatment market reach USD 1.98 Billion in 2022 and is expected to exhibit a CAGR of 5.3% over the forecast period 2023 to 2032 PUNE ...
Chromocell Therapeutics (CHRO) has filed to raise $11.5 million in an IPO of its units consisting of common stock and warrants, according to an S-1 registration statement. The firm is developing a ...
In human genetic studies, it was found that activating Kv7 channel mutations can overcome severe chronic EM pain caused by hereditary neuronal sodium ion channel activating mutations DELRAY BEACH, FL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results